REGENXBIO (NASDAQ:RGNX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of REGENXBIO (NASDAQ:RGNX) from a sell rating to a hold rating in a research note published on Saturday.

A number of other equities analysts have also commented on the stock. Royal Bank Of Canada lifted their price target on shares of REGENXBIO from $17.00 to $19.00 and gave the company an “outperform” rating in a research report on Friday. Barclays dropped their target price on shares of REGENXBIO from $50.00 to $37.00 and set an “overweight” rating on the stock in a report on Friday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of REGENXBIO in a report on Wednesday, October 8th. Chardan Capital reaffirmed a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a research report on Monday, September 8th. Finally, HC Wainwright reissued a “buy” rating and set a $34.00 price objective on shares of REGENXBIO in a research report on Tuesday, October 7th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $28.63.

REGENXBIO Price Performance

Shares of NASDAQ:RGNX opened at $11.02 on Friday. The stock has a market capitalization of $557.83 million, a P/E ratio of -3.18 and a beta of 1.22. The business has a 50-day moving average of $10.82 and a two-hundred day moving average of $9.52. REGENXBIO has a fifty-two week low of $5.03 and a fifty-two week high of $13.93.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($1.20) EPS for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.18. REGENXBIO had a negative return on equity of 78.29% and a negative net margin of 110.29%.The business had revenue of $29.73 million for the quarter, compared to analyst estimates of $24.41 million. As a group, research analysts expect that REGENXBIO will post -4.84 EPS for the current fiscal year.

Insider Buying and Selling at REGENXBIO

In related news, CEO Curran Simpson sold 20,811 shares of REGENXBIO stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $12.62, for a total transaction of $262,634.82. Following the sale, the chief executive officer directly owned 216,162 shares of the company’s stock, valued at $2,727,964.44. This trade represents a 8.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 36,169 shares of company stock valued at $416,598 in the last three months. 12.79% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On REGENXBIO

Several large investors have recently added to or reduced their stakes in RGNX. JPMorgan Chase & Co. grew its holdings in shares of REGENXBIO by 4.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,037,248 shares of the biotechnology company’s stock worth $38,959,000 after purchasing an additional 185,223 shares in the last quarter. Profund Advisors LLC lifted its position in REGENXBIO by 11.8% in the third quarter. Profund Advisors LLC now owns 14,444 shares of the biotechnology company’s stock worth $139,000 after purchasing an additional 1,523 shares during the period. Jones Financial Companies Lllp boosted its stake in REGENXBIO by 44.4% during the third quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock worth $40,000 after buying an additional 1,270 shares in the last quarter. Thrivent Financial for Lutherans bought a new stake in REGENXBIO in the 3rd quarter valued at $338,000. Finally, AlphaQuest LLC increased its holdings in REGENXBIO by 42.7% in the 3rd quarter. AlphaQuest LLC now owns 42,904 shares of the biotechnology company’s stock valued at $414,000 after buying an additional 12,828 shares during the period. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.